Targeting bacterial membrane proteins for new antimicrobial strategies

细菌抗生素耐药性在公共卫生和生物防御方面都是一个全球性的健康挑战，但大型制药公司的新抗生素开发正在下降。学术和生物技术公司正在填补该领域的空白，导致开发能够提供新的安全有效抗生素的新治疗技术。我们将与DSTL合作，使用各种新的方法研究负责选定病原体细胞壁生物合成的膜蛋白复合体。我们将把重点放在细菌细胞壁的组装上，这是现有抗生素的一个有效靶点，在过去十年中，来自机制研究和细菌细胞生物学进展的新见解提供了与这一过程相关的新机会和新理解，为新抗生素的发现提供了新的视角。Www.warwick.ac.uk/go/ropergroup

Bacterial antibiotic resistance is a global health challenge in both public health and biodefence but new antibiotic development by large pharma is in decline. The void in the sector is being filled by academic and biotech companies leading to the development of new therapeutic technologies that can provide new safe and effective antibiotics. We will collaborate with Dstl to investigate the membrane protein complexes responsible for cell wall biosynthesis in selected pathogens using a variety of new approaches. We will focus on the assembly of the bacterial cell wall, a validated target for existing antibiotics where novel insight in the past decade from mechanistic studies and advances in bacterial cell biology, have provided new opportunity and understanding related to this process offering fresh perspectives in new antibiotic discovery. www.warwick.ac.uk/go/ropergroup